Tadeusz Robak, MD, PhD, discusses the results of the 7-year follow-up analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.
Tadeusz Robak, MD, PhD, professor of hematology, Medical University of Lodz, chief, Department of Hematology, Copernicus Memorial Hospital, Lodz, Poland, discusses the results of the 7-year follow-up analysis of the phase 3 RESONATE-2 trial (NCT01722487) in chronic lymphocytic leukemia (CLL).
During the 2021 International Workshop on CLL, updated long-term findings from RESONATE-2 were presented in a virtual poster. The results showed that at a median follow-up of up to 7 years, the median progression-free survival (PFS) was not reached with ibrutinib (Imbruvica) compared with 15 months with chlorambucil (HR, 0.160; 95% CI, 0.111-0.230). Moreover, 61% of patients who received ibrutinib vs 9% of patients who received chlorambucil were estimated to be progression free and alive at 6.5 years, Robak says.
Additionally, the PFS advantage with ibrutinib vs chlorambucil was observed irrespective of age, Rai status at baseline, ECOG performance status at baseline, size of bulky disease, presence or absence of high-risk features like TP53 mutations, 11q deletions, and/or unmutated IGHV, and ß2-microglobulin level at baseline, Robak concludes.